Treatment of small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 3, 2014, Pages 257-270

  Morabito, Alessandro ^a   Carillio, Guido ^b   Daniele, Gennaro ^a   Piccirillo, Maria Carmela ^a   Montanino, Agnese ^a   Costanzo, Raffaele ^a   Sandomenico, Claudia ^a   Giordano, Pasqualina ^a   Normanno, Nicola ^a   Perrone, Francesco ^a   Rocco, Gaetano ^a   Di Maio, Massimo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Immunomodulators; Radiotherapy; Small cell lung cancer; Targeted agents

Indexed keywords

ALPHA INTERFERON; AMRUBICIN; AMUVATINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IFOSFAMIDE; IPILIMUMAB; IRINOTECAN; LINSITINIB; OBLIMERSEN; PACLITAXEL; PANOBINOSTAT; PAZOPANIB; ROMIDEPSIN; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VINCRISTINE; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; CANCER REGRESSION; CARDIOTOXICITY; CHEMORADIOTHERAPY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ESOPHAGITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; SKULL IRRADIATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY, ADJUVANT; SMALL CELL LUNG CARCINOMA;

EID: 84904599936     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.03.003     Document Type: Review

References (80)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
3. Stupp R., Monnerat C., Turrisi A.T., Perry M.C., Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004, 45:105-117.
4. Mountain C.F. The international system for staging lung cancer. Semin Surg Oncol 2000, 18:106-115.
5. Jhun B.W., Lee K.J., Jeon K., et al. Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system. Lung Cancer 2013, 81:65-70.
6. Stahel R., Thatcher N., Fruh M., et al. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011, 22:1973-1980.
7. Seifter E.J., Ihde D.C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988, 15:278-299.
8. Feld R., Evans W.K., DeBoer G., et al. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 1984, 2:294-304.
9. Johnson D. Management of small cell lung cancer: current state of the art. Chest 1999, 116:525S-530S.
10. Evans W.K., Osoba D., Feld R., Shepherd F.A., Bazos M.J., DoBoer G. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985, 1:65-71.
11. Sierocki J.S., Hilaris B.S., Hopfan S., et al. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979, 63:1593-1597.
12. Evans W.K., Shepherd F.A., Feld R., Osoba D., Dang P., Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985, 3:1471-1477.
13. Sundstrøm S., Bremnes R.M., Kaasa S., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20:4665-4672.
14. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992, 327:1618-1624.
15. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992, 10:890-895.
16. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J., Kester A., Rutten I., Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006, 17:543-552.
17. Sun J.M., Ahn Y.C., Choi E.K., et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 2013, 24(8):2088-2092.
18. Fried D.B., Morris D.E., Poole C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004, 22(23):4837-4845.
19. Spiro S.G., James L.E., Rudd R.M., et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 2006, 24(24):3823-3830.
20. Hirsch F.R., Paulson O.B., Hansen H.H., Vraa-Jensen J. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer 1982, 50:2433-2437.
21. Arriagada R., Le Chevalier T., Borie F., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995, 87:183-190.
22. Gregor A., Cull A., Stephens R.J., et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997, 33:1752-1758.
23. Aupérin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999, 341:476-484.
24. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999, 17:1794-1801.
25. Roth B.J., Johnson D.H., Einhorn L.H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:282-291.
26. Fukuoka M., Furuse K., Saijo N., et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83:855-861.
27. Loehrer P.J, Ansari R., Gonin R., et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995, 13:2594-2599.
28. Pujol J.L., Daurès J.P., Rivière A., et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001, 93:300-308.
29. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
30. Hermes A., Bergman B., Bremnes R., et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008, 26:4261-4267.
31. Hanna N., Bunn P.A., Langer C., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
32. Lara P.N, Natale R., Crowley J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
33. Jiang J., Liang X., Zhou X., et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010, 5(6):867-873.
34. Fink T.H., Huber R.M., Heigener D.F., et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol 2012, 7:1432-1439.
35. Sun Y., Cheng Y., Hao X., et al. Result of phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small cell lung cancer. J Clin Oncol 2013, 31. [suppl; abstr 7507].
36. Ihde D.C., Mulshine J.L., Kramer B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994, 12:2022-2034.
37. Furuse K., Fukuoka M., Nishiwaki Y., et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998, 16:2126-2132.
38. Humblet Y., Symann M., Bosly A., et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987, 5:1864-1873.
39. Leyvraz S., Pampallona S., Martinelli G., et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008, 100:533-541.
40. Giaccone G., Dalesio O., McVie G.J., et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993, 11:1230-1240.
41. Schiller J.H., Adak S., Cella D., DeVore R.F., Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:2114-2122.
42. Rossi A., Garassino M.C., Cinquini M., et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010, 70:119-128.
43. Mattson K., Niiranen A., Pyrhönen S., et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 1992, 28A:1387-1391.
44. Kelly K., Crowley J.J., Bunn P.A., et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995, 13(12):2924-2930.
45. Lee S.M., Woll P.J., Rudd R., et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009, 101:1049-1057.
46. Pujol J.L., Breton J.L., Gervais R., et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007, 25:3945-3951.
47. Reck M., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013, 24(1):75-83.
48. Rossi A., Di Maio M., Chiodini P., Rudd R.M., Okamoto H., Skarlos D.V. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012, 30:1692-1698.
49. Jeremic B., Shibamoto Y., Nikolic N., et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999, 17:2092-2099.
50. Früh M., De Ruysscher D., Popat S., Crinò L., Peters S., Felip E. ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl. 6):99-105.
51. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672.
52. Cheng S., Evans W.K., Stys-Norman D., Shepherd F.A. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in evidence-based care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007, 2:348-354.
53. Owonikoko T.K., Behera M., Chen Z., et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012, 7:866-872.
54. Postmus P.E., Berendsen H.H., van Zandwijk N., Splinter T.A., Burghouts J.T., Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987, 23:1409-1411.
55. Giaccone G., Ferrati P., Donadio M., Testore F., Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987, 23:1697-1699.
56. Wakuda K., Kenmotsu H., Naito T., et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol 2013, [Epub ahead of print].
57. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
58. Shipley D.L., Hainsworth J.D., Spigel D.R., et al. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC). A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2006, 24(18S):7083.
59. Shah C., Ready N., Perry M., et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007, 57:84-88.
60. Spigel D.R., Greco F.A., Burris H.A., et al. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clin Lung Cancer 2011, 12:187-191.
61. O'Brien M.E., Ciuleanu T.E., Tsekov H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447.
62. Eckardt J.R., von Pawel J., Pujol J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
63. Jotte R., Von Pawel J., Spigel D.R., et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer. J Clin Oncol 2011, 29:15s. [suppl; abstr 7000].
64. Ciuleanu T., Samarzjia M., Demidchik Y., et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010, 28:15s. [suppl; abstr 7002].
65. Allen J.W., Moon J., Gadgeel S.M., et al. SWOG 0802: a randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). J Clin Oncol 2012, 30. (suppl; abstr 7005).
66. Ready N.E., Dudek A.Z., Pang H.H., et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011, 29:4436-4441.
67. Spigel D.R., Greco F.A., Zubkus J.D., et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009, 4:1555-1560.
68. Jalal S., Bedano P., Einhorn L., et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 2010, 5:2008-2011.
69. Mountzios G., Emmanouilidis C., Vardakis N., et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer 2012, 77:146-150.
70. Spigel D.R., Townley P.M., Waterhouse D.M., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011, 29:2215-2222.
71. Ready N., Pang H., Gu L., et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: a randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE). J Clin Oncol 2013, 31. [suppl; abstr 7506].
72. Arnold A.M., Seymour L., Smylie M., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007, 25(27):4278-4284.
73. Paik P.K., Rudin C.M., Pietanza M.C., et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011, 74:481-485.
74. Belani C.P., Dahlberg S.E., Rudin C.M., et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508). J Clin Oncol 2013, 31. [suppl; abstr 7508].
75. Glisson B., Kazarnowicz A., Nackaerts K., et al. A multicenter, double-blind, placebo-controlled, randomized phase 2 study of ganitumab or rilotumumab with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC). J Thorac Oncol 2013, 8(Suppl. 2):S220. [abstr O21.05].
76. Havel L., Dees C., Lockhart C., et al. MLN8237 (alisertib), a selective Aurora A Kinase (AAK) inhibitor, in patients with relapsed/refractory small cell lung cancer (SCLC): phase 2 results. J Thorac Oncol 2013, 8(Suppl. 2):S221. (abstr O21.06).
77. Spigel D.R., Socinski M.A. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC. J Thorac Oncol 2013, 8:587-598.
78. Jackman D.M., Johnson B.E. Small-cell lung cancer. Lancet 2005, 366:1385-1396.
79. Peifer M., Fernandez-Cuesta L., Sos M.L., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1112.
80. Morabito A., Di Maio M., De Maio E., Normanno N., Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand?. Ann Oncol 2006, 17(Suppl. 7):128-131.